drugset / Trial / NCT04221906

Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test

NCT04221906

Phase 1 Completed 15 enrolled Boston Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is being conducted to evaluate the safety of topical BOS-475 compared to topically applied comparator formulations and vehicle.

Timeline

Start
2020-01-06
Primary completion
2020-03-06
Completion
2020-03-06

Drugs

EvaluationDrugModalityDoseRoute
Subject BOS-475 Unknown 0.5 % Topical
Subject BOS-475 Unknown 1 % Topical
Subject BOS-475 Unknown 2 % Topical
Comparator Betamethasone Other / unclassified 0.1 % Topical
Comparator Calcipotriol Small molecule 0.005 % Topical

Indications